Genetic testing is also available for squamous lung cancer. About 10-20% of squamous lung cancers also have genetic mutations, such as EGFR mutations or ALK mutations, of course. The incidence of genetic mutations in squamous lung cancer is significantly lower than that of lung adenocarcinoma, and about 10%-20% of squamous lung cancers in China also have genetic mutations. The presence of genetic mutations provides the basis for the use of targeted drugs. The current treatment regarding squamous lung cancer is mainly chemotherapy, or immune checkpoint inhibitors. If there is genetic mutation, treatment can be increased. The use of targeted drugs can be taken orally, which has less side effects, higher efficiency and good tolerability, and genetic testing for lung squamous carcinoma is also available in clinical practice, especially for non-smoking squamous carcinoma.